Medistem Inc. Annual Letter to Shareholders
SAN DIEGO, CA–(Marketwire – Jan 4, 2013) – Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders. Dear Fellow Shareholders,
January 14, 2013
SAN DIEGO, CA–(Marketwire – Jan 4, 2013) – Medistem Inc. ( PINKSHEETS : MEDS ) today issues the following letter to shareholders. Dear Fellow Shareholders,
Part 1: Dr. Riordan discusses mesenchymal stem cell sources from umbilical cord Wharton’s jelly, stem cell expansion, therapeutic potential of umbilical cord mesenchymal stem cells
In Part 1 of 3 Dr. Paz discusses his internal medicine background in New York and Texas, and how he got involved with stem cell
Current treatments with Adipose-, Bone Marrow- and Cord Blood-derived stem cells. Autism, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis and Osteoarthritis treatments are outlined. Dr.
Eduardo Mansilla,1,* Vanina Díaz Aquino,1 Daniel Zambón,2 Gustavo Horacio Marin,1 Karina Mártire,1 Gustavo Roque,1 Thomas Ichim,3 Neil H. Riordan,3 Amit Patel,4 Flavio Sturla,5 Gustavo Larsen,6,
As Kenny Kelley of Glenburn awaits an infusion of adult stem cells at a Panamanian city in November 2011, a Panamanian physician holds two syringes
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2025, Stem Cell Insitute Panama. All rights reserved.